These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38643252)

  • 21. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients.
    Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Tsukii R; Takahashi H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Jan; 14(1):2451. PubMed ID: 38291120
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration.
    Sotani R; Matsumiya W; Kim KW; Miki A; Yasuda E; Maeda Y; Hara R; Kusuhara S; Nakamura M
    Graefes Arch Clin Exp Ophthalmol; 2023 Aug; 261(8):2359-2366. PubMed ID: 36971800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
    Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
    Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term outcomes of intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 choroidal neovascularization including polypoidal choroidal vasculopathy.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2021 Mar; 11(1):6759. PubMed ID: 33762600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results.
    Khanani AM; Aziz AA; Khan H; Gupta A; Mojumder O; Saulebayeva A; Abbey AM; Almeida DRP; Avery RL; Banda HK; Barakat MR; Bhandari R; Chang EY; Haug SJ; London NJS; Mein L; Sheth VS; Wolfe JD; Singer MA; Danzig CJ
    Eye (Lond); 2023 Dec; 37(17):3574-3581. PubMed ID: 37173428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study.
    Tanaka K; Koizumi H; Tamashiro T; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Kasai A; Ogasawara M; Shintake H; Sugano Y; Yamamoto A; Kataoka K; Hasegawa T; Izumi T; Kawai M; Maruko R; Sekiryu T; Okada AA; Iida T; Mori R
    Jpn J Ophthalmol; 2022 Jul; 66(4):379-385. PubMed ID: 35595951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term outcomes of intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
    Matsumoto H; Hoshino J; Nakamura K; Nagashima T; Akiyama H
    Graefes Arch Clin Exp Ophthalmol; 2023 Oct; 261(10):2945-2952. PubMed ID: 37195339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab.
    Sim SY; Chalkiadaki E; Koutsocheras G; Nicholson L; Sivaprasad S; Patel PJ; Selvam S; Pal B; Keane PA; Bhatia B; Hamilton R;
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39084554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.
    Mehta N; Fong RD; Wilson M; Moussa K; Emami-Naeini P; Moshiri A; Yiu G; Park SS
    Clin Ophthalmol; 2023; 17():657-665. PubMed ID: 36880020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
    Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
    Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brolucizumab for Wet Age-Related Macular Degeneration: One-Year Real-World Experience from a Tertiary Center.
    Scupola A; Carlà MM; Boselli F; Giannuzzi F; De Filippis A; Fossataro C; Minnella AM; D'Amico G; Coppola G; Savastano MC; Sammarco MG; Rizzo S
    Ophthalmologica; 2023; 246(1):58-67. PubMed ID: 36843038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual outcomes of intraocular inflammation after brolucizumab injection in Japanese patients with neovascular age-related macular degeneration.
    Hirono K; Maruyama-Inoue M; Yanagi Y; Kadonosono K
    PLoS One; 2024; 19(4):e0302295. PubMed ID: 38635732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].
    Book M; Ziegler M; Rothaus K; Faatz H; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
    Ophthalmologe; 2022 Mar; 119(3):258-264. PubMed ID: 34351479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative Efficacy of Brolucizumab in the Treatment of Neovascular Age-Related Macular Degeneration: A Systematic Literature Review and Network Meta-Analysis.
    Finger RP; Dennis N; Freitas R; Quenéchdu A; Clemens A; Karcher H; Souied EH
    Adv Ther; 2022 Aug; 39(8):3425-3448. PubMed ID: 35678996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, open-label, multicenter study of switching to brolucizumab with or without a loading dose for patients with suboptimal anatomically controlled neovascular age-related macular degeneration-the FALCON study.
    Holz FG; Schmitz-Valckenberg S; Wolf A; Agostini H; Lorenz K; Pielen A; Feltgen N; Guthoff R; Quiering C; Clemens A; Jaeger K
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2695-2702. PubMed ID: 35188581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.